Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for IDH1- and IDH2-mutated acute myeloid leukaemia, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Ivosidenib-azacitidine or venetoclax-azacitidine first, or all three together.
Managing differentiation syndrome without stopping an effective drug.
Isoform switching and second-site mutations that escape a single IDH inhibitor.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)
Relapsed/refractory IDH1-mutated AML
OS 24.
A milestone in how this cancer is treated.
OS 14.